Liposomal/LNP Formulation of Drugs
Polymun has unique know-how and technology for the development and manufacturing of liposomal and lipid nanoparticle (LNP) formulations.
Reference Projects
CUSTOMER/PARTNER | PRODUCT | SCOPE AT POLYMUN | STATUS |
---|---|---|---|
Ethris GmbH Germany | Lipid nanoparticle formulation of mRNA coding for type III interferon (ETH47) | Development of manufacturing process and analytical methods, GMP production of drug product | Phase 1, USA |
International AIDS Vaccine Initiative (IAVI) USA | Saponin/MPLA nanoparticles (SMNP) developed at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT) as adjuvant for HIV candidate vaccines | Development of process and analytical methods, GMP production of drug product | Phase 1, USA |
Omega Therapeutics Inc. USA | Omega Epigenomic Controller (OEC) mRNA medicine delivered by lipid nanoparticles (OTX-2002) | Establishing of manufacturing process and analytical methods, GMP production of drug product | Phase 1/2 |
BioNTech SE Germany | Lipid nanoparticle formulation of mRNA coding for Plasmodium falciparum (causative pathogen for Malaria) antigens | Establishing of manufacturing process and analytical methods, GMP production | Phase 1/2, USA |
BioNTech SE Germany | Lipid nanoparticle formulation of mRNA coding for Mycobacterium tuberculosis antigens | Establishing of manufacturing process and analytical methods, GMP production | Phase 1, Germany & South Africa (as of June 2023) |
BioNTech SE Germany | Lipid nanoparticle formulation of mRNA coding for HSV-2 antigens | Establishing of manufacturing process and analytical methods, GMP production | Phase 1, USA (as of June 2023) |
Arcturus Therapeutics Inc. USA | Lipid nanoparticle formulation of mRNA as coronavirus vaccine | Implementing of manufacturing process and analytical methods, GMP production | Phase 1/2, Singapore, Phase 3, Vietnam, Market Japan |
CureVac Germany | Lipid nanoparticle formulation of surface protein encoding mRNA as coronavirus vaccine | Establishing of manufacturing process and analytical methods, GMP production | Phase 3, Europe & Latin America |
BioNTech SE Germany | Lipid nanoparticle formulations of surface protein encoding mRNA and self-amplifying RNA as coronavirus vaccine | Establishing of manufacturing process and analytical methods, GMP production | Market Europe, US, UK, Canada, etc. |
BioNTech SE Germany | Plain liposomes as carrier for mRNA for cell therapy | Establishing of manufacturing process and analytical methods, GMP production | Preclinical |
BioNTech SE Germany | Lipid nanoparticle formulation of mRNA coding for a therapeutic antibody | Establishing of manufacturing process and analytical methods, GMP production | Phase 2, USA, Canada, Singapore & Spain |
Signpath Pharma USA | Liposomal formulation of curcumin for the treatment of cancer | Formulation and process development, GMP production | Phase 2, USA |
Imperial College London UK | Lipid nanoparticle formulation of self-amplifying RNA as coronavirus vaccine | Establishing of manufacturing process and analytical methods, GMP production | Phase 1, UK, Uganda |
InteRNA Technologies B.V. The Netherlands | Lipid nanoparticle formulation of miRNA INT-1B3 for treatment of advanced solid tumors | Establishing of manufacturing process and analytical methods, GMP production | Phase 1, Europe |
MiNA Therapeutics Ltd. UK | Liposomal saRNA MTL-CEBPA with Smarticle technology for cancer treatment | Process development, GMP production | Phase 2, Singapore, Taiwan, USA, UK |
Mirna Therapeutics Inc. USA | Liposomal miRNA MRX34 with Smarticle technology for cancer treatment | Process development, GMP production | Phase 1, USA |
Dicerna Pharmaceuticals, Inc. USA | Liposomal formulation of siRNA | Process development, GMP production | Preclinical and clinical |
Wittycell SA (now Abivax) France | Liposomal adjuvant WTCc | Formulation and process development, GMP production | Phase 1/2a, South Africa |
AC Immune SA Switzerland | ACI-24, liposomal Alzheimer’s disease vaccine with MPLA adjuvant | Process development, GMP production | Phase 2, Europe & USA |
EuroNeut-41, EU FP7 project coordinated by Sanofi-Pasteur France | Liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccine | Formulation and process development, GMP production | Phase 1 completed, UK |
ProNAi Inc. USA | Liposomal of DNAi PNT100 with Smarticle technology for cancer treatment | Process development, GMP production | Phase 2 completed, USA |
Sanochemia Pharmazeutika AG Austria | Liposomal formulation of galantamine for the treatment of neuropathic pain | Formulation and process development, GMP production | Phase 1/2a completed, Bulgaria |
CUSTOMER/PARTNER
Ethris GmbHGermany
PRODUCT
Lipid nanoparticle formulation of mRNA coding for type III interferon (ETH47)SCOPE AT POLYMUN
Development of manufacturing process and analytical methods, GMP production of drug productSTATUS
Phase 1, USA
CUSTOMER/PARTNER
International AIDS Vaccine Initiative (IAVI)USA
PRODUCT
Saponin/MPLA nanoparticles (SMNP) developed at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT)as adjuvant for HIV candidate vaccines
SCOPE AT POLYMUN
Development of process and analytical methods, GMP production of drug productSTATUS
Phase 1, USA
CUSTOMER/PARTNER
Omega Therapeutics Inc.USA
PRODUCT
Omega Epigenomic Controller (OEC) mRNA medicine delivered by lipid nanoparticles (OTX-2002)SCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP production of drug productSTATUS
Phase 1/2
CUSTOMER/PARTNER
BioNTech SEGermany
PRODUCT
Lipid nanoparticle formulation of mRNA coding for Plasmodium falciparum (causative pathogen for Malaria) antigensSCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 1/2, USA
CUSTOMER/PARTNER
BioNTech SEGermany
PRODUCT
Lipid nanoparticle formulation of mRNA coding for Mycobacterium tuberculosis antigensSCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 1, Germany & South Africa (as of June 2023)
CUSTOMER/PARTNER
BioNTech SEGermany
PRODUCT
Lipid nanoparticle formulation of mRNA coding for HSV-2 antigensSCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 1, USA (as of June 2023)
CUSTOMER/PARTNER
Arcturus Therapeutics Inc.USA
PRODUCT
Lipid nanoparticle formulation of mRNA as coronavirus vaccineSCOPE AT POLYMUN
Implementing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 1/2, Singapore, Phase 3, Vietnam, Market Japan
CUSTOMER/PARTNER
CureVacGermany
PRODUCT
Lipid nanoparticle formulation of surface protein encoding mRNA as coronavirus vaccineSCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 3, Europe & Latin America
CUSTOMER/PARTNER
BioNTech SEGermany
PRODUCT
Lipid nanoparticle formulations of surface protein encoding mRNA and self-amplifying RNA as coronavirus vaccineSCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Market Europe, US, UK, Canada, etc.
CUSTOMER/PARTNER
BioNTech SEGermany
PRODUCT
Plain liposomes as carrier for mRNA for cell therapySCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Preclinical
CUSTOMER/PARTNER
BioNTech SEGermany
PRODUCT
Lipid nanoparticle formulation of mRNA coding for a therapeutic antibodySCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 2, USA, Canada, Singapore & Spain
CUSTOMER/PARTNER
Signpath PharmaUSA
PRODUCT
Liposomal formulation of curcumin for the treatment of cancerSCOPE AT POLYMUN
Formulation and process development, GMP productionSTATUS
Phase 2, USA
CUSTOMER/PARTNER
Imperial College LondonUK
PRODUCT
Lipid nanoparticle formulation of self-amplifying RNA as coronavirus vaccineSCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 1, UK, Uganda
CUSTOMER/PARTNER
InteRNA Technologies B.V.The Netherlands
PRODUCT
Lipid nanoparticle formulation of miRNA INT-1B3 for treatment of advanced solid tumorsSCOPE AT POLYMUN
Establishing of manufacturing process and analytical methods, GMP productionSTATUS
Phase 1, Europe
CUSTOMER/PARTNER
MiNA Therapeutics Ltd.UK
PRODUCT
Liposomal saRNA MTL-CEBPA with Smarticle technology for cancer treatmentSCOPE AT POLYMUN
Process development, GMP productionSTATUS
Phase 2, Singapore, Taiwan, USA, UK
CUSTOMER/PARTNER
Mirna Therapeutics Inc.USA
PRODUCT
Liposomal miRNA MRX34 with Smarticle technology for cancer treatmentSCOPE AT POLYMUN
Process development, GMP productionSTATUS
Phase 1, USA
CUSTOMER/PARTNER
Dicerna Pharmaceuticals, Inc.USA
PRODUCT
Liposomal formulation of siRNASCOPE AT POLYMUN
Process development, GMP productionSTATUS
Preclinical and clinical
CUSTOMER/PARTNER
Wittycell SA(now Abivax) France
PRODUCT
Liposomal adjuvant WTCcSCOPE AT POLYMUN
Formulation and process development, GMP productionSTATUS
Phase 1/2a, South Africa
CUSTOMER/PARTNER
AC Immune SASwitzerland
PRODUCT
ACI-24, liposomal Alzheimer’s disease vaccine with MPLA adjuvantSCOPE AT POLYMUN
Process development, GMP productionSTATUS
Phase 2, Europe & USA
CUSTOMER/PARTNER
EuroNeut-41, EU FP7 project coordinated by Sanofi-PasteurFrance
PRODUCT
Liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccineSCOPE AT POLYMUN
Formulation and process development, GMP productionSTATUS
Phase 1 completed, UK
CUSTOMER/PARTNER
ProNAi Inc.USA
PRODUCT
Liposomal of DNAi PNT100 with Smarticle technology for cancer treatmentSCOPE AT POLYMUN
Process development, GMP productionSTATUS
Phase 2 completed, USA
CUSTOMER/PARTNER
Sanochemia Pharmazeutika AGAustria
PRODUCT
Liposomal formulation of galantamine for the treatment of neuropathic painSCOPE AT POLYMUN
Formulation and process development, GMP productionSTATUS
Phase 1/2a completed, Bulgaria